Slow acetylators of isoniazid are more prone to develop:
**Question:** Slow acetylators of isoniazid are more prone to develop:
**Core Concept:**
The question is testing our understanding of isoniazid pharmacokinetics and pharmacodynamics, particularly focusing on acetylation status and its relation to drug toxicity. Isoniazid is an essential drug in the treatment of tuberculosis (TB). Acetylation is a process where an enzyme called Acetyl-CoA Carboxylase (ACC) catalyzes the addition of an acetyl group to various molecules. In this context, slow acetylators refer to individuals with reduced activity of the ACC enzyme, leading to slower acetylation of isoniazid and increased drug exposure.
**Why the Correct Answer is Right:**
Slow acetylators are more prone to develop isoniazid-induced toxicity (Pyridoxine-Dependent Neuronal Ceroid Lipofuscinoses, PDNCL) due to the following reasons:
1. **Increased drug exposure:** Slow acetylators have a slower clearance of isoniazid, leading to higher drug concentrations in the body. This increased drug exposure increases the risk of toxicity.
2. **Lower pyridoxine (vitamin B6) levels:** Slow acetylators require higher doses of pyridoxine (vitamin B6) for proper isoniazid detoxification. Pyridoxine plays a crucial role in the conversion of isoniazid to its active, toxic form, INH-R, which is responsible for the toxicity.
3. **Increased formation of INH-R:** Since slow acetylators have lower pyridoxine levels, the conversion of isoniazid to its toxic form (INH-R) is increased, leading to isoniazid-induced toxicity.
**Why Each Wrong Answer is Incorrect:**
A. (Option A) Rapid acetylators are more prone to develop: This is incorrect because rapid acetylators have efficient isoniazid detoxification, which minimizes the risk of toxicity.
B. (Option B) Slow acetylators are more prone to develop: This is incorrect as explained earlier, but it is less relevant to the actual question.
C. (Option C) Lower doses of pyridoxine are required: This is incorrect, as slow acetylators require higher doses of pyridoxine for proper isoniazid detoxification.
D. (Option D) Increased pyridoxine levels: This is incorrect because slow acetylators have lower pyridoxine levels, which leads to increased INH-R formation and increased risk of toxicity.
**Clinical Pearl:**
A high-dose pyridoxine prophylaxis is recommended for patients with a history of isoniazid-induced neuropathy. This prophylactic measure helps in preventing the development of isoniazid-induced neuropathy in slow acetylators.